1. Zenas BioPharma is like a 'kinder, gentler' Biogen for B-cell autoimmune therapies, aiming to inhibit rather than deplete B cells.

2. Zenas BioPharma aims to be a future AbbVie for immunology franchises, starting with a novel B-cell inhibitor for multiple autoimmune conditions.

Major Product Candidate

• Obexelimab: A bifunctional monoclonal antibody in clinical development for the treatment of various autoimmune diseases, including IgG4-RD, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.

null

Lonnie Moulder, Chief Executive Officer and Chairman of the Board of Directors

Mr. Moulder is the Founder of Zenas BioPharma and has served as its Chief Executive Officer since August 2023, and as Chairman and a member of the board of directors since 2020. He has been the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund, since March 2019. Mr. Moulder has built and sold biotech companies for a combined total exceeding $10 billion, including the sale of TESARO to GlaxoSmithKline for $5.1 billion, Abraxis BioScience to Celgene for $2.9 billion, and MGI PHARMA to Eisai for $3.9 billion. He was recognized as Entrepreneur of the Year by Ernst & Young in 2017.

Jennifer Fox, Chief Business Officer and Chief Financial Officer

Ms. Fox has served as Zenas BioPharma's Chief Business Officer and Chief Financial Officer since December 2023. She is an experienced finance and corporate development executive with over 25 years of experience in corporate finance and healthcare investment banking, during which she advised numerous private and public companies on strategy, financings, and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, Inc., a publicly traded biotechnology company. Before Nuvation Bio, she was a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup, and also held senior investment banking positions at Deutsche Bank, Bear Stearns, Bank of America, and Prudential Securities.

Joe Farmer, President and Chief Operating Officer

Mr. Farmer serves as President and Chief Operating Officer. He is an accomplished biopharma executive with approximately 25 years of transactional and operational experience across all stages of development for emerging biotechnology companies, from discovery through commercialization. Prior to Zenas, Mr. Farmer was Chief Operating Officer at Xilio Therapeutics. Before Xilio, he served as General Counsel and Corporate Secretary at TESARO, where he led global legal, compliance, and government affairs functions and was a key member of the leadership team during its acquisition by GlaxoSmithKline in 2019.

Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer

Dr. von Moltke was appointed Head of Research and Development and Chief Medical Officer at Zenas BioPharma in March 2025, bringing over three decades of experience in drug development with expertise in autoimmune diseases. She previously served as Chief Medical Officer at Seres Therapeutics, with functional oversight of clinical development, sciences and operations, regulatory, and medical affairs. Her career includes significant leadership roles at Alkermes, Inc., where she was Senior Vice President and Head of Clinical Development, and at Sanofi/Genzyme Corporation, where she served as Vice President, Clinical and Exploratory Pharmacology. Dr. von Moltke also served as President of the American College of Clinical Pharmacology.

Haley Laken, Ph.D., Chief Scientific Officer

Dr. Laken was appointed Chief Scientific Officer of Zenas BioPharma in April 2025. She brings over two decades of leadership experience in research, development operations, scientific assessment, and strategy. Before joining Zenas, Dr. Laken served as Chief Operating Officer at Tabby Therapeutics, a privately held biotech company. She held roles of increasing responsibility at Jounce Therapeutics, culminating as Chief Development Officer, and served in a senior program leadership role at TESARO, where she led multiple biologic development programs. Dr. Laken also held strategic drug development leadership roles at Rhythm Pharmaceuticals, Pfizer, and Wyeth.

The key risks for Zenas BioPharma (ZBIO) are:

1. Clinical Trial and Regulatory Approval Risk: Zenas BioPharma is a clinical-stage company with no products approved for commercial sale and no revenue generated from product sales. The company's entire business and future revenue generation depend on the successful completion of clinical trials for its lead product candidate, obexelimab, across its various indications (IgG4-RD, MS, SLE, wAIHA), and subsequently obtaining regulatory approvals from health authorities. Failure in any of these critical stages due to issues with efficacy, safety, or other regulatory hurdles would fundamentally undermine the company's prospects.
2. Product Candidate Concentration Risk: Zenas BioPharma's strategy is heavily centered on developing obexelimab as its lead "I&I franchise" product candidate for multiple autoimmune diseases. While pursuing several indications, the company's pipeline is currently reliant on the success of this single bifunctional monoclonal antibody. Should obexelimab fail to demonstrate sufficient efficacy or an acceptable safety profile, or encounter unforeseen development or commercialization challenges, the company's entire business model would be severely impacted due to its lack of other late-stage diversified product candidates.

The primary drivers of future revenue growth for Zenas BioPharma (ZBIO) over the next 2-3 years are centered on the successful development and commercialization of its lead product candidate, obexelimab, across multiple autoimmune disease indications:

1. Successful Clinical Development and Regulatory Approval of Obexelimab for IgG4-RD: Zenas BioPharma is currently conducting a registration-directed Phase 3 trial for obexelimab in immunoglobulin G4-related disease (IgG4-RD). Successful completion of this trial and subsequent regulatory approval would mark the company's first potential product launch and revenue generation.
2. Commercial Launch and Market Penetration of Obexelimab for IgG4-RD: Following regulatory approval for IgG4-RD, the effective commercial launch and successful market penetration of obexelimab within this indication will directly drive initial revenue growth. The company estimates a diagnosed population of approximately 20,000 IgG4-RD patients in the United States, representing a significant commercial opportunity upon launch.
3. Advancement and Expansion of Obexelimab into Additional Autoimmune Disease Indications: Zenas BioPharma is also developing obexelimab for multiple sclerosis (MS) and systemic lupus erythematosus (SLE) through Phase 2 trials, and for warm autoimmune hemolytic anemia (wAIHA) through an ongoing Phase 2/3 trial. Positive clinical trial outcomes and progression of obexelimab into later-stage development and eventual approval in these indications, which represent significantly larger patient populations (estimated at 650,000 for MS, 172,000 for SLE, and 40,000 for wAIHA in the U.S.), would substantially expand obexelimab's total addressable market and serve as major drivers for sustained future revenue growth.

Share Issuance

• Zenas BioPharma completed an initial public offering (IPO) in September 2024, raising approximately $258.7 million in gross proceeds, including the full exercise of the underwriters' option to purchase additional shares. Net proceeds from the IPO totaled $234.4 million through the sale of 13.23 million shares at $17 per share.
• In October 2025, the company secured a $120 million private placement by issuing approximately 6.3 million shares to institutional and accredited investors at $19.00 per share.
• Prior to its IPO, Zenas BioPharma raised a total of $318 million across three funding rounds, with its largest, a Series C round, occurring in May 2024 for $200.15 million.

Inbound Investments

• Zenas BioPharma entered into a revenue participation and funding agreement with Royalty Pharma, which will provide up to $300 million in consideration, including an upfront payment of $75 million.
• The company successfully completed a Series C funding round in May 2024, raising $200.15 million, co-led by SR One, New Enterprise Associates, Norwest Venture Partners, and Delos Capital Partners.
• A private placement completed in October 2025 brought in $120 million from institutional and accredited investors, as well as company directors and officers.

Outbound Investments

• Zenas BioPharma made a strategic investment through a license agreement with InnoCare, which included a $35.0 million upfront payment for exclusive development and manufacturing rights for product candidates, such as orelabrutinib. A $5.0 million deposit related to this upfront payment was recognized as acquired in-process research and development expenses in the quarter ended September 30, 2025.

Capital Expenditures

• Capital expenditures were reported as -$92,000 in the last 12 months, and $0.00 in the most recent quarter.
• The company anticipates that its cash, cash equivalents, and investments will cover its operating expenses and capital expenditure requirements into the fourth quarter of 2026.
• The primary focus of capital allocation is on supporting ongoing research and development activities and clinical trials for its lead product candidates, obexelimab and orelabrutinib.